エピソード

  • PFE Today - Jul 15: Bearishness Sparks Conversations

    PFE Today - Jul 15: Bearishness Sparks Conversations
    2026/07/15
    Hey there! It’s Joey, your friendly longtime investor, breaking down the stock scene for you. Today, we’re talking about Pfizer, and it was a green day for them—up about 1.36%. Not a massive jump, but hey, we’ll take what we can get, right?

    So, what happened? Well, Pfizer managed to bounce back a bit today after a rough patch. After taking a hit recently, the stock saw some nice movement, but let’s be real, it’s still not back to where it wants to be. Volume was pretty low compared to usual, which tells me not a ton of action was happening.

    Now, why did this happen? There’s been a lot of chatter about bearish sentiments surrounding Pfizer and even Gilead Sciences, with some folks thinking this might be a contrarian opportunity. Basically, some investors are looking at the current dip and thinking, "Hey, maybe this is a chance to buy low." But others are still feeling the sting from Pfizer’s earlier 21% slump, making them cautious. Plus, there's buzz about Pfizer having the highest-yielding dividend in the S&P 500, which can be a double-edged sword—great for income, but it raises questions about sustainability.

    Oh, and there was some talk about a competitor, BioCryst Pharmaceuticals, having a rough day, which might’ve helped Pfizer look a little better in comparison. Sometimes it’s just about how you stack up against the competition, right?

    One thing worth keeping an eye on? The ongoing discussions about Pfizer’s dividend. Investors are definitely paying attention to how that plays out, especially with all the recent ups and downs.

    So, that’s the scoop on Pfizer today! It’s a bit of a mixed bag, but at least it’s not a total disaster. Remember, this is just for your info and entertainment—no financial advice here, folks! Catch you later!
    続きを読む 一部表示
    2 分
  • PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer

    PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer
    2026/07/14
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Pfizer today. So, PFE had a red day, dropping about 0.8%. Ouch, right?

    Let’s get into it. Today was a bit rough for Pfizer. The stock got hit as news rolled in about drug pricing deals from Donald Trump that are shaking things up for big pharma. Investors were clearly feeling the weight of that news. Plus, there was a lot of chatter about some disappointing results from a lung cancer trial. That overshadowed Pfizer’s win with Ibrance, which is supposed to be a big deal. So yeah, it seems like people were hitting the sell button pretty fast.

    Now, why all the fuss? Well, it looks like these drug pricing deals could mean tighter profit margins for companies like Pfizer. The market's not really loving that, especially when you throw in a couple of price target cuts from big firms. BMO just slashed their target to $30 from $34, and Guggenheim did something similar, dropping it to $35. That’s not great for investor confidence. And when you mix that with the disappointment from the lung cancer trial, it’s no wonder folks are feeling skittish.

    One thing worth mentioning is that Pfizer did get FDA approval for something recently, but the market’s reaction was pretty muted. It’s like, “Yeah, cool, but what have you done for me lately?” That kind of vibe can really affect how stocks move, and today was a clear example of that.

    So, to wrap it all up: Pfizer’s facing some headwinds with drug pricing changes and trial results that didn’t quite hit the mark. It’s a tough spot, but that’s just how investing goes sometimes. Remember, this is just for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • PFE Today - Jul 13: Price Target Cuts Hit Hard

    PFE Today - Jul 13: Price Target Cuts Hit Hard
    2026/07/13
    Hey there! It's Joey, your friendly investor buddy, breaking down what went down today with Pfizer. So, PFE had a bit of a green day, up about 1.82%. Not too shabby, right?

    But hold on, it wasn’t all sunshine and rainbows. The stock kinda had a rough ride earlier in the week. Today’s uptick was like a small bounce back after some recent price target cuts from analysts. Guggenheim lowered its target to $35, and BMO Capital followed suit, dropping theirs to $30. That’s never a fun thing to hear as a shareholder. People were probably feeling a bit jittery about it.

    Now, let’s talk about the why behind today’s action. Despite those price cuts, Pfizer scored a big win with FDA approval for its Lyme disease vaccine, showing a promising 70% efficacy. That’s incredible news, but it seems like Wall Street wasn’t super excited about it. The reaction was kinda muted, like when you tell your friends about a cool new game and they’re just like, “Yeah, cool.” It’s a bummer when good news doesn’t translate to excitement on the stock side, right?

    And get this—there's a lot going on in the healthcare space right now. While Pfizer's vaccine news is solid, the market's still buzzing about other big players making moves, like Novo Nordisk launching a subscription model for Wegovy. Everyone's trying to figure out how these shifts impact the whole scene.

    So, yeah, that’s the lowdown on Pfizer today. Always a mix of wins and losses in the stock game. Just remember, this is all info for you to chew on, not financial advice or anything. Keep your head up, and I’ll catch you later!
    続きを読む 一部表示
    1 分
  • PFE Today - Jul 12: Lung Cancer Trial Disappointment

    PFE Today - Jul 12: Lung Cancer Trial Disappointment
    2026/07/12
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what happened today with Pfizer. So, PFE had a red day, dropping about a third of a percent. Nothing too crazy, but still not great.

    What went down? Well, it looks like folks are still feeling the sting from some disappointing news about a lung cancer trial. Yeah, that one stung. People were really hoping for a win there, but it didn’t pan out. On the flip side, there was some good news too—Pfizer got a thumbs up from the FDA for a new bladder cancer treatment. But the lung cancer news overshadowed that, and you know how it goes; bad news travels faster.

    So why the drop? Investors are reacting to the lung cancer trial disappointment. It seems like that’s weighing heavy on everyone’s minds. Even though they had a win with the bladder cancer regimen, the market's mood was already set. When people see a setback like that, they tend to hit the sell button fast. It’s like a chain reaction, you know?

    And just to throw a little extra info your way, Pfizer also had news about their Lyme disease vaccine showing some solid efficacy. But honestly, it feels like that news got lost in the shuffle today.

    One thing worth knowing is that Pfizer’s got more in the pipeline, and they’re still pushing forward with their research. So, while today wasn’t a banner day, there's still stuff happening behind the scenes.

    Alright, that’s a wrap for today’s recap! Hope that helped clear things up. Remember, I’m just here to share the info, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • PFE Today - Jul 11: Pfizer's Slow Day

    PFE Today - Jul 11: Pfizer's Slow Day
    2026/07/11
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor, breaking down the day’s action. Today, we’re talking about Pfizer. It was a bit of a rough ride, closing down just a smidge—like, down 0.33%. Yeah, that one stung a little.

    So, what went down? Well, the stock kinda just sat there, barely moving. It wasn’t a huge day for trading, with volume coming in lower than usual. Just 27 million shares changed hands, which is less than half of what we typically see. A slow bleed for sure.

    Now, let’s get into the why behind this action. There’s been a lot of chatter about Pfizer lately. Some folks are saying it’s a solid defensive pick in this market. But then, you’ve got Jim Cramer throwing some shade, saying he can’t see where the growth is coming from. Ouch! That’s a tough spot to be in, especially when people are looking for excitement. On the flip side, some articles are highlighting Pfizer’s potential in the AI healthcare space, saying it’s one of three picks worth a closer look. So, it’s like a mixed bag of opinions out there.

    And here’s something interesting: there’s chatter about a post-pandemic turnaround happening for Pfizer. They’re seen as undervalued right now, which might mean some upside in the future if they play their cards right. But until then, it’s just a lot of waiting and seeing.

    Anyway, that’s the scoop on Pfizer today. If you’re in it for the long haul, hang tight and keep an eye on the news. Remember, I’m just here to keep you informed and entertained, not to give financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • PFE Today - Jul 10: Mixed Signals in Pharma

    PFE Today - Jul 10: Mixed Signals in Pharma
    2026/07/10
    Hey there! It’s Joey here, your go-to guy for breaking down the stock scene. I’ve been at this investing game for years, and today we’re talking about Pfizer. So, was it a green or red day? Well, it was a slight red day, down just a smidge—like, 0.08%.

    Now, what happened? The stock kinda just floated around. It didn’t really get smoked, but it also didn’t pop off. Volume was way lower than usual, which means not a lot of folks were trading it today. It's like everyone was just chillin’, not making any big moves.

    So, why the slow bleed? Well, there’s some chatter about how Pfizer’s growth isn't looking super exciting right now. An article compared it to McDonald’s, saying one has real growth potential while the other is just kinda hanging out, paying dividends and waiting for something to happen. That's a tough spot to be in, ya know? Investors want to see some action, not just a wait-and-see game.

    Plus, there was some buzz about AstraZeneca crashing a bit, which dragged Pfizer along with it. When one big player stumbles, it can send shockwaves through the whole sector. People start getting nervous, and that’s never good for the vibe.

    And hey, here’s something to keep an eye on: there’s been talk about AI in healthcare, and Pfizer got a mention as one of the stocks worth a look in that space. So, while it’s not exactly a rocket ship right now, there’s potential for some interesting developments down the line.

    Alright, that’s a quick scoop on Pfizer today. Just remember, this is all for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • PFE Today - Jul 09: AstraZeneca's Crash Boosts Rivals

    PFE Today - Jul 09: AstraZeneca's Crash Boosts Rivals
    2026/07/09
    Hey there! It’s Joey, your friendly investor buddy. Let’s break down what went down with Pfizer today. So, PFE had a pretty chill day, closing up just a little, like 0.54%. Not exactly fireworks, but hey, it’s something, right?

    So, here’s the scoop. Pfizer didn’t have a huge move on its own, but it kinda rode the coattails of AstraZeneca’s rough day. AstraZeneca took a dive, crashing about 8%. That’s a big deal! When one of your rivals gets smoked like that, it can give others a little boost. Pfizer and a couple of other competitors saw some green as folks shifted their focus. It’s like the old saying goes—when one ship sinks, others might float a bit higher.

    Now, why did AstraZeneca crash? Well, it looks like they had some bad news that spooked investors. Not exactly the best headlines for them, and that ripple effect gave Pfizer a little lift. But let’s be real, nobody's really popping champagne over a 0.54% gain. It’s more like a gentle nudge forward rather than a major win.

    Oh, and here’s something interesting on the horizon. Pfizer's Lyme disease vaccine is showing some solid promise, with reports saying it has 70% efficacy. That’s some good news, especially considering the whole vaccine game is still a hot topic. It might not be a game-changer right away, but it’s definitely something to keep an eye on.

    So, to wrap it up, Pfizer had a bit of a quiet day, but it got a slight lift thanks to AstraZeneca’s misfortune. Not the most exciting movement, but hey, every little bit counts, right? Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
  • PFE Today - Jul 09: AstraZeneca Drama Boosts Rivals

    PFE Today - Jul 09: AstraZeneca Drama Boosts Rivals
    2026/07/09
    Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Pfizer today. So, we’re talking about PFE, and it had a green day, up just a bit by about half a percent. Not a huge jump, but hey, green is good!

    Now, here’s the scoop. Pfizer started the day kinda slow but picked up some steam after some news about AstraZeneca. They took a hit, dropping about 8%. That news kinda shook things up in the market, and investors seemed to think, “Hey, if AstraZeneca’s struggling, maybe there’s a chance for Pfizer and some of the other big pharma players to step in.” So, people started hitting that buy button for Pfizer, and that helped it stay in the green.

    But let’s talk about the bigger picture. A few things are swirling around Pfizer lately. There’s chatter about their Lyme disease vaccine showing some solid numbers—70% efficacy, which is pretty impressive. That’s the kind of news that can get people excited. But then there’s also the other side of the coin. Some folks are saying that Pfizer's dividend is looking a bit risky right now. That’s a mixed bag, for sure. And just to throw a little more drama into the mix, there’s a story about a former Pfizer building crumbling, which is kinda wild. I mean, that’s not exactly the best look for a company, right?

    Oh, and just to keep you in the loop, there’s been some talk about what to look for before buying into pharma stocks. So, if you’re thinking about it, just keep your eyes peeled.

    Alright, that’s the lowdown on Pfizer today! It’s always a rollercoaster in the stock world. Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later, and happy investing!
    続きを読む 一部表示
    2 分